Contribute Try STAT+ Today

About

Come here for the cutting edge

Technologies and procedures that would have been science fiction are now the reality of medicine. Our 2021 STAT Breakthrough Science Summit will take you inside these innovations, examining how they're being developed, adopted, and paid for. We'll also take a look at the breakthroughs that haven't yet hit the market, but have the potential to redefine health and medicine in the years to come.

Speakers

Hear from industry-shaping speakers

Check back in as we continue to add more speakers and apply today to be considered for speaking opportunities for this and future events.
All speakers subject to change.

James P. Allison, Ph.D.

James P. Allison, Ph.D.

Regental Professor and Chair of Immunology at The University of Texas MD Anderson Cancer Center

Seng H. Cheng, Ph.D.
SPONSOR SPEAKER

Seng H. Cheng, Ph.D.

Senior Vice President and Chief Scientific Officer, Rare Disease Research Unit, Pfizer

Francis S. Collins, M.D., Ph.D.

Francis S. Collins, M.D., Ph.D.

Director, National Institutes of Health

Damian Garde
STAT Moderator

Damian Garde

National Biotech Reporter, STAT

Bobby Gaspar, M.D., Ph.D.

Bobby Gaspar, M.D., Ph.D.

Chief Executive Officer and Co-Founder, Orchard Therapeutics

Matthew Herper
STAT Moderator

Matthew Herper

Senior Writer, Medicine; Editorial Director of Events, STAT

Katherine High, M.D.

Katherine High, M.D.

President, Therapeutics, AskBio

Kathrin U. Jansen, Ph.D.

Kathrin U. Jansen, Ph.D.

Senior Vice President and Head of Vaccine Research and Development, Pfizer

Katalin Karikó, Ph.D.

Katalin Karikó, Ph.D.

Senior Vice President, BioNTech SE; Adjunct Associate Professor, Perelman School of Medicine, University of Pennsylvania

David R. Liu, Ph.D.

David R. Liu, Ph.D.

Vice-Chair and Core Faculty Member of the Broad Institute; Professor of Chemistry and Chemical Biology at Harvard University; HHMI Investigator

Robert Nelsen

Robert Nelsen

Co-founder and Managing Director, ARCH Venture Partners

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer, Eli Lilly

Ugur Sahin, M.D.

Ugur Sahin, M.D.

Co-Founder and CEO, BioNTech

Elizabeth H.Z. Thompson, Ph.D.
SPONSOR SPEAKER

Elizabeth H.Z. Thompson, Ph.D.

Executive Vice President, Research and Development, Horizon Therapeutics

Agenda

Join us July 13th and 14th

We'll bring you inside the transformation of health care with probing interviews, lively panels, and exciting demos with experts from across the industry. Check back in as we continue to release sessions.

July 13, 2021

Diabetes. Alzheimer’s. Covid. What’s next for Lilly?

David Ricks, chairman and chief executive officer, Eli Lilly Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

In the past year, Eli Lilly unveiled data for a promising diabetes drug, a closely watched Alzheimer’s medicine, and one of the first successful treatments for Covid. We’ll take stock.

The future of gene therapy

Katherine High, M.D., president, therapeutics, AskBio Bobby Gaspar, M.D., Ph.D. chief executive officer, Orchard Therapeutics Sek Kathiresan, M.D., co-founder and chief executive officer, Verve Therapeutics Damian Garde, national biotech reporter, STAT (moderator)

Kathy High led the development of the first gene therapy. Now she, along with several other top executives, will guide us through what’s next.

Antiracist medicine

Uché Blackstock, M.D., founder and CEO, Advancing Health Equity Nicholas St. Fleur, general assignment reporter and associate editorial director of events, STAT (moderator)

Together, the pandemic and a racial reckoning pulled back the curtain on the deep inequities in American medicine. Now that they are in full view, how can they be addressed?

Go big. And go wild.

Robert Nelsen, co-founder and managing director, ARCH Venture Partners Additional speakers to be announced

Bob Nelsen is the mind behind some of biotech’s biggest financings. Come hear what he believes is coming next — from blood tests to detect cancer to dramatic changes in how medicines are manufactured.

Breakout Sessions

Breakout session with Bob Nelson, co-founder and managing director, ARCH Venture Partners Breakout session with Kathrin Jansen, Ph.D., senior vice president and head of vaccine research and development, Pfizer Breakout session with Sek Kathiresan, M.D., co-founder and chief executive officer, Verve Therapeutics

Exclusive to attendee pass holders.

July 14, 2021

After a pandemic, a future

Francis S. Collins, M.D., Ph.D., director National Institutes of Health

The National Institutes of Health were instrumental in the development of the Covid-19 vaccines. Now, the NIH is setting its sights on changing the way we battle disease.

Does genetics + CRISPR = medicine?

Francis S. Collins, M.D., Ph.D., director National Institutes of Health David R. Liu, Ph.D., vice-chair and core faculty member of the Broad Institute, professor of chemistry and chemical biology at Harvard University, and HHMI Investigator Additional speakers to be announced

Progeria is a fatal disorder that causes children to age rapidly. But treatments are being developed. Could gene editing be part of the solution?

For mRNA, a long trek from idea to vaccine

Katalin Karikó, senior vice president, BioNTech SE; adjunct associate professor, Perelman School of Medicine, University of Pennsylvania Damian Garde, national biotech correspondent, STAT (moderator)

For years, Katalin Karikó’s quest to turn the body’s messenger into medicines collected rejections. She’ll reflect on the journey.

The partnership behind the first Covid-19 vaccine

Kathrin U. Jansen, Ph.D., senior vice president and head of vaccine research and development, Pfizer Ugur Sahin, chairman and CEO, BioNTech

Every week during the pandemic, our speakers have gotten on a call together. Here's how that partnership resulted in the first approved Covid-19 vaccine.

Secrets of cancer immunotherapy

James P. Allison, Ph.D., regental professor and chair of immunology at The University of Texas MD Anderson Cancer Center

He’s an iconoclast, a Nobel laureate, and a harmonica player. Hear Jim Allison will tell the story of how cancer immunotherapy broke through and share his ideas on where the field is going.

Breakout sessions

Breakout session with Katalin Kariko, Ph.D., senior vice president, BioNTech SE Breakout session with James Allison, Ph.D., Regental Professor and Chair of Immunology at The University of Texas MD Anderson Cancer Center Breakout session with a featured speaker (to be announced) and STAT's Nicholas St. Fleur

Exclusive to attendee pass holders.

Location

Virtual Event

The 2021 STAT Breakthrough Science Summit will be held virtually via a livestream.

© Mapbox © OpenStreetMap

Attend

Register to attend the Breakthrough Science Summit

Use your STAT+ subscriber login at registration to unlock an exclusive 20% discount!

Viewer Pass ($200)

  • Access to all main-stage programming including live interviews, keynotes, and panel discussions via event platform
  • The ability to network with fellow attendees and browse sponsor booths via STAT's virtual event platform
  • The opportunity to chat with fellow summit ticket holders, ask questions of our speakers, and respond to polls during live programming

Attendee Pass, by application only ($400)

All the benefits of the Viewer Pass, plus:

  • The opportunity to attend two curated breakout sessions via Zoom. You'll turn on your audio and video for real-time conversations
  • A STAT Breakthrough Science Summit welcome gift in the mail (While supplies last, U.S. shipping only) and other exclusive STAT content
  • Early access to STAT's virtual event platform for an extended networking period


Get our Morning Rounds newsletter

A free, daily guide to news in health and medicine

Sponsors

A special thanks to our partners

Presenting Sponsor

Premium Sponsors

Supporting Sponsor

Contact

Stay in the loop

Join our email list

Sign up today for summit news and updates

Please enter a valid email address.

Questions?

Email us any questions or concerns

[email protected]

Terms & Conditions